Open-Angle Glaucoma Animal Model With IFN-γ-Induced Trabecular Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing animal models for open-angle glaucoma fail to accurately replicate the chronic elevation of intraocular pressure and anatomical changes characteristic of human primary open-angle glaucoma, often causing structural disruption and unstable pressure elevation.
Innovation Solution
A method involving anterior chamber injection of IFN-γ in specific pathogen-free animals, such as C57BL/6J mice, Sprague-Dawley rats, and Japanese big-eared white rabbits, to induce stable and chronic elevation of intraocular pressure, mimicking the pathophysiological changes of open-angle glaucoma by affecting trabecular meshwork function without mechanical disruption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional IOP-elevation methods (anterior chamber microsphere injection, laser photocoagulation, suprascleral vein occlusion) are used, then intraocular pressure can be elevated, but the anatomical structure of aqueous humor circulation is significantly disrupted and the model does not accurately replicate chronic IOP elevation
Solution Approach 1:
The patent replaces mechanical methods of IOP elevation (microsphere injection, laser photocoagulation, physical occlusion) with a biochemical approach using IFN-γ injection. This substitution achieves IOP elevation through biological mechanisms (trabecular meshwork cell dysfunction) rather than mechanical disruption, thereby maintaining normal anatomical structure while replicating the functional pathology of POAG
Solution Approach 2:
The patent changes the fundamental parameter of IOP elevation from acute/mechanical to chronic/biochemical. By using IFN-γ injection, the model achieves sustained IOP elevation over time that mimics the progressive nature of human POAG, rather than the abrupt, short-lived pressure increases caused by mechanical methods
2Duration of action of moving object
If mechanical IOP elevation methods are used, then IOP can be increased rapidly, but the duration of elevated IOP is short and unstable
Solution Approach 1:
The patent implements continuous action by using repeated IFN-γ injections at intervals to maintain sustained IOP elevation. This creates a continuous pathological state that mimics chronic POAG, unlike mechanical methods that produce transient, unstable pressure increases
Solution Approach 2:
The patent employs periodic IFN-γ injection intervals to maintain chronic IOP elevation. This periodic administration creates a sustained pathological state that accurately replicates the progressive, chronic nature of human POAG over extended periods
3Reliability
If anterior chamber microsphere injection is used, then IOP elevation can be achieved, but corneal endothelial decompensation and inflammatory responses are significantly exacerbated
Solution Approach 1:
The patent replaces mechanical microsphere injection with biochemical IFN-γ injection, eliminating the physical foreign body that causes corneal endothelial damage and intense inflammation. This substitution achieves IOP elevation through trabecular meshwork cell dysfunction without the harmful mechanical effects
Solution Approach 2:
The patent uses IFN-γ as a biochemical intermediary to induce trabecular meshwork cell dysfunction. This intermediary approach achieves IOP elevation through physiological mechanisms rather than direct mechanical obstruction, thereby avoiding the harmful effects of foreign body injection while maintaining model reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method creates a reliable animal model with sustained intraocular pressure elevation, open chamber angle, trabecular meshwork dysfunction, and retinal ganglion cell loss, closely resembling human open-angle glaucoma, with a high success rate and minimal structural alteration.
Implementation Method 1
induces the necroptosis mechanism of trabecular meshwork cells by injecting IFN-γ into the anterior chamber
Implementation Method 2
2 μl of air is slowly introduced to form a complete bubble in the anterior chamber. The needle remains in position for 30 seconds post-injection to allow the bubble to seal the puncture and prevent backflow
Data Source
AI summary
The present disclosure pertains to the field of animal disease models, specifically to a method for constructing an animal model of open-angle glaucoma. In this model, the pathogenesis of open-angle glaucoma is mimicked by inducing necroptosis in trabecular meshwork cells through the injection of IFN-γ into the anterior chamber. This process leads to the inhibition of trabecular meshwork activity and functional impairment, resulting in elevated intraocular pressure and subsequent optic nerve changes indicative of glaucoma. The pathophysiological alterations observed in the animal model closely resemble those seen in human open-angle glaucoma, including chamber angle opening, trabecular meshwork dysfunction, increased intraocular pressure, and loss of RGCs.